The Food and Drug Administration (FDA) has updated its adverse drug event reporting forms to begin tracking incidents related to hemp-derived cannabinoid products such as CBD. The change to the federal documents—which are used by healthcare professionals, consumers and companies to report adverse experiences with drugs, cosmetics and other products—received sign-off from the White House…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
